A Randomized, Double-Blind, Placebo-Controlled Study of Single and Multiple Ascending Doses of PN-881 in Healthy Subjects
Latest Information Update: 10 Aug 2026
At a glance
- Drugs PN 881 (Primary)
- Indications Hidradenitis suppurativa; Plaque psoriasis; Psoriatic arthritis; Spondylarthritis
- Focus Adverse reactions
- Sponsors Protagonist Therapeutics
Most Recent Events
- 05 Aug 2026 Status changed from recruiting to completed.
- 16 Dec 2025 Status changed from not yet recruiting to recruiting.
- 12 Sep 2025 New trial record